Advertisement

The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty

  • Yasuhisa Izushi
  • Naofumi Shiota
  • Tomonori Tetsunaga
  • Kenichi Shimada
  • Takashi Egawa
  • Tsukasa Kiuchi
  • Toru Sato
  • Ritsugi Takuma
  • Yoichiro TakamiEmail author
Original Article • HIP - ARTHROPLASTY

Abstract

Background

Postoperative anemia is a common complication after total hip arthroplasty (THA). However, the effect of edoxaban on postoperative anemia after THA remains unclear. Here, we retrospectively evaluated the clinical assessment of postoperative anemia and the associated changes of coagulation parameters in patients undergoing thromboprophylaxis with edoxaban compared with fondaparinux as a conventional anticoagulant thromboprophylactic agent after THA.

Methods

One hundred and forty-nine patients who underwent THA from July 2010 to June 2012 were divided into two groups, according to whether they were operated on before or after the approval of edoxaban: the fondaparinux group (Group F: 86 patients) and the edoxaban group (Group E: 63 patients). The frequency of postoperative anemia and blood coagulation values were investigated.

Results

Postoperative anemia developed more frequently in Group E than in Group F after surgery. However, the degree of postoperative anemia showed no significant difference between the groups. Meanwhile, prothrombin time (PT), prothrombin time-international normalized ratio (PT-INR), and activated partial thromboplastin time were markedly higher in patients with edoxaban-associated postoperative anemia, which showed an increased potential to predict the occurrence of postoperative anemia. Additionally, both PT and PT-INR in Group E were also correlated with the volume of estimated blood loss.

Conclusion

The frequency of postoperative anemia was increased in patients treated with edoxaban, compared to fondaparinux, after THA. Edoxaban thromboprophylaxis might, therefore, require more careful monitoring to prevent postoperative anemia. Additionally, particular prolongation of PT and PT-INR induced by edoxaban treatment might predict postoperative anemia.

Keywords

Edoxaban Total hip arthroplasty Postoperative anemia Prothrombin time 

Notes

Acknowledgements

We thank Yusuke Ookura, Akimasa Yoshida, Kazuma Koga, Yuko Kuwada, Anna Ueno, Satomi Tani, Shunki Ishihara for helpful discussion and assistance with all our data analyses. Repeatedly, all of them helped with the data extraction from their respective database and ensured the high quality of the data by numerous quality checks.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

590_2018_2212_MOESM1_ESM.pptx (126 kb)
Supplementary material 1 (PPTX 126 kb)

References

  1. 1.
    Steuber TD, Howard ML, Nisly SA (2016) Strategies for the management of postoperative anemia in elective orthopedic surgery. Ann Pharmacother 50:578–585CrossRefPubMedGoogle Scholar
  2. 2.
    Spahn DR (2010) Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 113:482–495CrossRefPubMedGoogle Scholar
  3. 3.
    Liu X, Zhang X, Chen Y, Wang Q, Jiang Y, Zeng B (2011) Hidden blood loss after total hip arthroplasty. J Arthroplasty 26(1100–1105):e1Google Scholar
  4. 4.
    Kawaji H, Ishii M, Tamaki Y, Sasaki K, Takagi M (2012) Edoxaban for prevention of venous thromboembolism after major orthopedic surgery. Orthop Res Rev 4:53–64CrossRefGoogle Scholar
  5. 5.
    Daiichi Sankyo Limited. Daiichi Sankyo launches LIXIANA®tablets (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopedic surgery: first direct oral factor Xa inhibitor available to Japanese patients. http://www.daiichisankyo.co.jp/news/detail/005457.html. Accessed 10 Jan 2018
  6. 6.
    Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T et al (2010) Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 104:642–649CrossRefPubMedGoogle Scholar
  7. 7.
    Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 29:2439–2446CrossRefPubMedGoogle Scholar
  8. 8.
    Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116:492–499CrossRefPubMedGoogle Scholar
  9. 9.
    Eriksson BI, Bauer KA, Lassen MR, Turpie AG et al (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298–1304CrossRefPubMedGoogle Scholar
  10. 10.
    Izushi Y, Takami Y, Shiota N, Tetsunaga T, Ookura Y, Shimada K et al (2016) Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux. Biol Pharm Bull 39:516–523CrossRefPubMedGoogle Scholar
  11. 11.
    Carling MS, Jeppsson A, Eriksson BI, Brisby H (2015) Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. J Orthop Surg Res 10:48CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Thrombolysis 8:202–204CrossRefGoogle Scholar
  13. 13.
    Rogers BA, Cowie A, Alcock C, Rosson JW (2008) Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl 90:504–507CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    European Medicines Agency/Committee for Medicinal Products for Human Use (CHMP) (2013) Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143764.pdf. Accessed 7 Jan 2018
  15. 15.
    Sasaki H, Ishida K, Shibanuma N, Tei K, Tateishi H, Yoda A et al (2014) Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthoplasy. Int Orthop 38:525–529CrossRefPubMedGoogle Scholar
  16. 16.
    Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR (2012) Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 470:2605–2612CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232PubMedGoogle Scholar
  18. 18.
    Fahmy NR, Patel DG (1981) Hemostatic changes and postoperative deep-vein thrombosis associated with use of a pneumatic tourniquet. J Bone Joint Surg Am 63:461–465CrossRefPubMedGoogle Scholar
  19. 19.
    Langdown AJ, Field J, Grote J, Himayat H (2000) Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty 15:1009–1012CrossRefPubMedGoogle Scholar
  20. 20.
    Good L, Peterson E, Lisander B (2003) Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth 90:596–599CrossRefPubMedGoogle Scholar
  21. 21.
    Lisander B, Ivarsson I, Jacobsson SA (1998) Intraoperative autotransfusion is associated with modest reduction of allogeneic transfusion in prosthetic hip surgery. Acta Anaesthesiol Scand 42:707–712CrossRefPubMedGoogle Scholar
  22. 22.
    Ogata K, Mendell-Harary J, Tachibana M, Matsumoto H, Oguma T, Kojima M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753CrossRefPubMedGoogle Scholar
  23. 23.
    Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S (2011) Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost 105:1080–1090CrossRefPubMedGoogle Scholar
  24. 24.
    Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N et al (2012) Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. Thromb Res 130:514–519CrossRefPubMedGoogle Scholar
  25. 25.
    Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI (2010) Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol 4:5CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag France SAS, part of Springer Nature 2018

Authors and Affiliations

  • Yasuhisa Izushi
    • 1
    • 2
  • Naofumi Shiota
    • 3
  • Tomonori Tetsunaga
    • 4
  • Kenichi Shimada
    • 5
  • Takashi Egawa
    • 5
  • Tsukasa Kiuchi
    • 1
  • Toru Sato
    • 3
  • Ritsugi Takuma
    • 6
  • Yoichiro Takami
    • 5
    Email author
  1. 1.Department of PharmacyNational Hospital Organization Okayama Medical CenterOkayamaJapan
  2. 2.Department of PharmacologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  3. 3.Department of Orthopaedic SurgeryNational Hospital Organization Okayama Medical CenterOkayamaJapan
  4. 4.Department of Orthopaedic SurgeryOkayama University HospitalOkayamaJapan
  5. 5.Pharmaceutical Care and Health Sciences, School of PharmacyShujitsu UniversityOkayamaJapan
  6. 6.Department of PharmacyShikoku Medical Center for Children and AdultsKagawaJapan

Personalised recommendations